Holen Sie sich die Stockscreener-App
7.57
1.05%
-0.08
Schlusskurs vom Vortag:
$7.65
Offen:
$7.59
24-Stunden-Volumen:
4.89M
Relative Volume:
0.41
Marktkapitalisierung:
$8.02B
Einnahmen:
$140.98M
Nettoeinkommen (Verlust:
$-854.60M
KGV:
-8.8642
EPS:
-0.854
Netto-Cashflow:
$-299.31M
1W Leistung:
-0.92%
1M Leistung:
-3.93%
6M Leistung:
+27.33%
1J Leistung:
+179.34%
1-Tages-Spanne:
$7.4301
$7.59
1-Wochen-Bereich:
$7.42
$7.955
52-Wochen-Spanne:
$1.95
$12.43
Immunitybio Inc Stock (IBRX) Company Profile
Firmenname
Immunitybio Inc
Sektor
Branche
Telefon
(844) 696-5235
Adresse
3530 JOHN HOPKINS COURT, SAN DIEGO
Compare IBRX vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
7.57 | 8.20B | 140.98M | -854.60M | -299.31M | -0.854 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-12 | Fortgesetzt | BTIG Research | Buy |
| 2025-05-20 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-03-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-01-10 | Eingeleitet | BTIG Research | Buy |
| 2023-05-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-08-03 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Immunitybio Inc Aktie (IBRX) Neueste Nachrichten
147,000 Shares in ImmunityBio, Inc. $IBRX Purchased by Hussman Strategic Advisors Inc. - marketbeat.com
Does Adding Jim Yong Kim to Leadership Shift ImmunityBio’s Global Strategy Narrative (IBRX)? - simplywall.st
ImmunityBio Founder Pushes Back After FDA Warning Letter Over Anktiva Claims — Says Ad 'Never Aired At All' - Stocktwits
IBRX Stock In Spotlight: ImmunityBio To Unveil Fresh Anktiva And BCG Data Next Week - Stocktwits
IBRX Stock In Spotlight As FDA Scrutiny Prompts ImmunityBio To Withdraw Content, Tighten Oversight - Stocktwits
IBRX Stock Climbs Overnight: ImmunityBio Declares ‘All Systems Go’ For Dunkirk Anktiva Manufacturing Push - Stocktwits
ImmunityBio, Inc. (IBRX) options chain - Yahoo Finance UK
IBRX Stock Eyes Best Week Since February: Founder Highlights New Anktiva-NK Cell Therapy Study - Stocktwits
ImmunityBio, Inc. • Robinhood Token (IBRX) Price Prediction for 2026 to 2031 - Bybit
Archer Aviation (NYSE: ACHR) Among IBRX, JOBY, SCKT Leading Technology Stocks – Plus More in Focus - FinancialContent
ImmunityBio (IBRX) Tests Its Valuation After UAE ANKTIVA Approval Expands Its Reach - Sahm
ImmunityBio Names Former World Bank President Jim Yong Kim Vice Chairman - citybiz
ImmunityBio appoints Jim Yong Kim as vice chairman - Investing.com
ImmunityBio Appoints Dr. Jim Yong Kim, Former World Bank President and Global Health Leader, as Vice Chairman - ImmunityBio
Royal Bank of Canada Has $11.40 Million Holdings in ImmunityBio, Inc. $IBRX - marketbeat.com
Why ImmunityBio (IBRX) Is Up 6.6% After ANKTIVA’s UAE Expansion and Mixed Q2 Results – And What's Next - webull.com
ImmunityBio Founder Dr. Patrick Soon-Shiong to Speak at Milken In - The National Law Review
Analysts Have Been Trimming Their ImmunityBio, Inc. (NASDAQ:IBRX) Price Target After Its Latest Report - 富途牛牛
ImmunityBio (IBRX) Stock Looks Rich On Sales But Strong On Returns - finance.yahoo.com
ImmunityBio (IBRX) Stock May Trade At A Premium To Fair Value - Sahm
The Bull Case For ImmunityBio (IBRX) Could Change Following ANKTIVA’s Broad UAE Approval And Ongoing Losses - Yahoo Finance
ImmunityBio (IBRX) group led by Soon-Shiong holds 64.8% stake - Stock Titan
Q3 Earnings Estimate for ImmunityBio Issued By HC Wainwright - MarketBeat
IBRX Founder Soon-Shiong Bets On Anktiva's Next Growth Phase — ImmunityBio Posts Record Q2 Sales - Stocktwits
IBRX Q2 Earnings & Sales Beat Estimates on Strong Anktiva Uptake - Yahoo Finance
HC Wainwright Increases Earnings Estimates for ImmunityBio - MarketBeat
ImmunityBio | 10-Q: Q2 2026 Earnings Report - Moomoo
ImmunityBio Releases Q2 2026 Financial Results - AlphaStreet
ImmunityBio (NASDAQ:IBRX) Posts Earnings Results, Misses Estimates By $0.14 EPS - MarketBeat
ImmunityBio (NASDAQ:IBRX) Shares Gap Down on Disappointing Earnings - marketbeat.com
ImmunityBio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Bronstein, Gewirtz & Grossman, LLC Encourages ImmunityBio, Inc - The National Law Review
Immunitybio Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Immunitybio Inc earnings missed by $0.14, revenue topped estimates - Investing.com
Earnings Flash (IBRX) ImmunityBio, Inc. Reports Q2 Revenue $51.2M, vs. FactSet Est of $49.7M - marketscreener.com
ImmunityBio 2Q 2026: Revenue $51.24M, EPS ($0.22) — 10-Q Summary - TradingView
[10-Q] ImmunityBio, Inc. Quarterly Earnings Report - Stock Titan
ImmunityBio: Q2 Earnings Snapshot - Barchart.com
ImmunityBio posts Q2 2026 product revenue $50.7M; H1 revenue $94.8M, cash $357.4M - TradingView
ImmunityBio Q2 revenue rises 92% to record $50.7 million - Quiver Quantitative
Record Q2 revenue and higher net loss at ImmunityBio (NASDAQ: IBRX) - Stock Titan
ImmunityBio, Inc. (IBRX) Q2 2026 Earnings - 24/7 Wall St.
ImmunityBio Reports Record Q2 2026 Net Product Revenue of $50.7 Million, Up 92% Year-Over-Year; First-Half Revenue Up 121% to $94.8 Million - Business Wire
ImmunityBio, Inc. (IBRX) Stock Analysis: Assessing a 78% Potential Upside in Cutting-Edge Immunotherapy - DirectorsTalk Interviews
Weekly Recap: U.S. papillary-only label expansion and UAE ANKTIVA approval - TradingView
ImmunityBio, Inc. (IBRX) Options Chain - ca.finance.yahoo.com
Arete Wealth Advisors LLC Makes New Investment in ImmunityBio, Inc. $IBRX - MarketBeat
ImmunityBio receives UAE marketing authorizations for ANKTIVA across NMIBC and NSCLC - TradingView
ImmunityBio Achieves World's Broadest Bladder Cancer Approval as UAE Green Lights Lead Drug - Benzinga
IBRX Stock Jumps Overnight: UAE Grants Anktiva Broadest Approval Yet After Founder’s ‘July Birthday News’ Tease - TradingView
UAE Gives ANKTIVA World’s First Approval Across BCG-Unresponsive Bladder Cancer - Stock Titan
Finanzdaten der Immunitybio Inc-Aktie (IBRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):